Federal Circuit Upholds Block on Generic Version of Novartis’ Entresto by MSN Labs

The legal landscape surrounding the pharmaceutical industry continues to evolve as the full Federal Circuit has decided not to revisit a decision by a panel from January, which prohibits MSN Laboratories Pvt. Ltd. from launching a generic variant of Novartis’ widely successful cardiovascular medication, Entresto. This decision is a key moment in the ongoing legal proceedings concerning this treatment. For additional details on this development, refer to the full article.